Welcome to AstraZeneca United States

AstraZeneca, together with its global biologics research and development arm MedImmune, today revealed plans to bring together five of its Bay Area sites into one location in South San Francisco. The new site will be located in the Cove at Oyster Point with cutting-edge lab space and offices. More than 350 employees in existing AstraZeneca, Acerta Pharma, MedImmune, and Pearl R&D facilities will move to the new location beginning in Q4 2017. 

Positive results from the Phase III DURATION-8 trial demonstrated that BYDUREON (exenatide extended-release) for injectable suspension 2 mg once-weekly in combination with FARXIGA (dapagliflozin) 10 mg once-daily significantly reduced blood sugar as measured by HbA1c, versus the individual medicines alone in patients with type 2 diabetes inadequately controlled on metformin.

Results from pivotal Phase III trials presented at the European Respiratory Society (ERS) International Congress demonstrated that adding benralizumab to standard-of-care medicine significantly reduced exacerbations and improved lung function and asthma symptoms in severe asthma patients with an eosinophilic phenotype, as indicated by the presence of eosinophils in their blood.

Nine years ago, Danei Edelen was established in her career as a marketing executive and happily raising a family with her husband in Ohio. Then something unexpected happened. “After five nights of no sleep, hallucinations, I sought hospitalization,” Danei said. She subsequently learned she had experienced a psychotic break caused by an underlying and undiagnosed mental illness called bipolar disorder. 

“Leadership is surrounding yourself with others who do not think like you and bringing out the best in those people.”

“Fostering diversity does not need justification; it is simply the right thing to do.”

“Diversity fuels innovation; a team needs individuals who approach challenges differently.”  

These messages were among those heard by hundreds of our employees last month at the 5th Annual Women’s Summit held on our Gaithersburg campus. 

Cancer is one of mankind’s greatest scientific and health challenges. Today, nearly 14.5 million Americans^[1] have cancer and the total annual cost of their treatment is estimated at $125 billion^[2]. With astonishing numbers like these, it’s more important than ever before that patients receive the best care possible while effectively managing overall costs to the healthcare system.

Not long ago, Emma Waldman was a fifth grader just outside of Boston, Massachusetts, disengaged from her classes in science and math. “[They] were always hard to conceptualize, I never really saw them as practical or important,” says Emma.  She is certainly not alone; 83% of students in the United States are not proficient or not interested in science, technology, engineering and math (STEM) fields by eighth grade.

Cardiovascular and metabolic diseases are complex and require life-long attention. Patients need to address many factors — from preventive measures, to care at the onset of disease to ongoing disease management. Our goal at AstraZeneca is to reduce the high cost of long-term complications with comprehensive support programs and resources that provide a thoughtful, personalized approach. We do this to help patients adhere to their treatment, reduce re-admission rates and change the course of disease by improving quality of care and ensuring that innovative medicines are being researched and accessible to patients in a timely manner.